Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930's. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.
This research report categorizes the radiopharmaceuticals therapy and PET/SPECT imaging market on the basis of isotopes, routes of administration, applications, and geography; forecasting revenue, and analyzing trends. Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables covering the sub-segments. In addition, the report provides more than 16 company profiles covering all the sub-segments.
Read complete report summary and Table of Contents for the report on Nuclear Medicine Market.
This market research report provides insight into the use of imaging to assist surgical performance, with procedure and market data for the US, Europe, Asia and ROW for the following modalities:
Copyright©2010 PR Newswire.
All rights reserved